ANAB Anaptysbio Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ANAB

Price (delayed)

$45.59

Market cap

$1.36B

P/E Ratio

6.74

Dividend/share

N/A

EPS

$6.76

Enterprise value

$1.5B

?
Relative Growth: Rel. Growth: 97
Relative Strength: Rel. Strength: 33
Relative Valuation: Rel. Valuation: 80
Relative Profitability: Rel. Profitability: 99

AnaptysBio is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics. It is developing immune cell modulators, including two checkpoint agonists in clinical-stage development, for autoimmune and inflammatory disease: ...

Highlights
The company's gross profit has surged by 93% YoY and by 2.2% QoQ
ANAB's revenue has soared by 93% YoY and by 2.2% from the previous quarter
Anaptysbio's equity has soared by 124% YoY but it has decreased by 17% from the previous quarter
The company's quick ratio fell by 34% YoY and by 28% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.anaptysbio.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of ANAB

ANAB stock price

How has the Anaptysbio stock price performed over time
Intraday
-0.98%
1 week
-4.8%
1 month
-15.37%
1 year
40.45%
YTD
-5.96%
QTD
-9.29%

Financial performance

How have Anaptysbio's revenue and profit performed over time
Revenue
$237.61M
Gross profit
$237.61M
Operating income
$312.93M
Net income
$195.72M
Gross margin
100%
Net margin
82.4%
ANAB's net margin has soared by 177% YoY
The company's gross profit has surged by 93% YoY and by 2.2% QoQ
ANAB's revenue has soared by 93% YoY and by 2.2% from the previous quarter
The company's operating margin has surged by 71% YoY and by 39% QoQ

Price vs fundamentals

How does ANAB's price correlate with its fundamentals

Growth

What is Anaptysbio's growth rate over time

Valuation

What is Anaptysbio stock price valuation
P/E
6.74
P/B
125.34
P/S
5.62
EV/EBIT
100.17
EV/EBITDA
90.25
EV/Sales
6.31
Anaptysbio's equity has soared by 124% YoY but it has decreased by 17% from the previous quarter
ANAB's revenue has soared by 93% YoY and by 2.2% from the previous quarter
The stock's price to sales (P/S) is 81% less than its 5-year quarterly average of 29.9 and 14% less than its last 4 quarters average of 6.5

Efficiency

How efficient is Anaptysbio business performance
The return on invested capital has surged by 164% since the previous quarter and by 117% year-on-year
ANAB's return on sales has surged by 156% since the previous quarter and by 106% year-on-year

Dividends

What is ANAB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ANAB.

Financial health

How did Anaptysbio financials performed over time
The total assets is 3.5% more than the total liabilities
The company's quick ratio fell by 34% YoY and by 28% QoQ
The current ratio has declined by 32% year-on-year and by 26% since the previous quarter
Anaptysbio's equity has soared by 124% YoY but it has decreased by 17% from the previous quarter
ANAB's debt is down by 22% YoY and by 2.8% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.